| Author (Corporate) | European Commission: DG Communication |
|---|---|
| Series Title | Press Release |
| Series Details | IP/17/1323 (15.05.17) |
| Publication Date | 15/05/2017 |
| Content Type | News |
|
On 15 May 2017 the European Commission opened a formal investigation into concerns that Aspen Pharma had engaged in excessive pricing concerning five life-saving cancer medicines. The Commission investigated whether Aspen had abused a dominant market position in breach of EU antitrust rules. |
|
| Source Link | Link to Main Source http://europa.eu/rapid/press-release_IP-17-1323_en.htm |
| Subject Categories | Business and Industry |
| Countries / Regions | Europe |
